Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16‐positive oropharynx cancer.
- Resource Type
- Article
- Source
- Head & Neck; May2023, Vol. 45 Issue 5, p1281-1287, 7p
- Subject
CETUXIMAB TUMOR microenvironment OROPHARYNX TUMOR-infiltrating immune cells TYPE I interferons - Language
- ISSN
- 10433074